On June 8, 2018, CFDA approved the application for production registration of the Quadrivalent Influenza Vaccine produced by Hualan Biological Bacterin Co., Ltd. Hualan Bio became the first enterprise to produce the approved Quadrivalent Influenza Vaccine in China. Hualan Bio has the production capacity of producing 30 million doses of Quadrivalent Influenza Vaccine per year. Quadrivalent Influenza Vaccine on the market will play a crucial role in preventing and controlling the epidemic of influenza in autumn and winter in our country. Influenza is an acute respiratory infection caused by influenza virus, which is also a disease with strong infectivity and fast transmission speed. Influenza is easy to cause death due to serious complications such as pneumonia among infants, the elderly and patients with basic heart and lung diseases. At present, vaccination against influenza is recognized as the most effective measure to prevent influenza diseases and outbreaks.